150
Participants
Start Date
January 1, 2024
Primary Completion Date
December 24, 2024
Study Completion Date
December 24, 2025
Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
St. Peter's Health Partners Medical Associates, PC, Albany
Trident Medical Center, Charleston
Orlando Health, Orlando
Erlanger Medical Center, Chattanooga
Trinity Health-Michigan d/b/a Michigan Heart, Ann Arbor
Aurora Medical Group, Milwaukee
Kansas City Cardiac Arrhythmia Research Foundation, Overland Park
Shannon Clinic, San Angelo
Heart Rhythm Associates, The Woodlands
Methodist Texsan Hospital, San Antonio
University of California at San Diego (UCSD) Medical Center, San Diego
Lead Sponsor
Abbott Medical Devices
INDUSTRY